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Stereoselective synthesis of 2,6-trans-4-
oxopiperidines using an acid-mediated
6-endo-trig cyclisation†
Jonathan D. Bell,a Alexander H. Harkiss,a Christopher R. Wellaway b and
Andrew Sutherland *a
An acid-mediated 6-endo-trig cyclisation of amine-substituted enones has been developed for the
stereoselective synthesis of trans-6-alkyl-2-methyl-4-oxopiperidines. Performed under conditions that
prevent removal of the Boc-protecting group or acetal formation, the key cyclisation was found to gene-
rate cleanly the 4-oxopiperidine products in high overall yields from a wide range of alkyl substituted
enones. The synthetic utility of the trans-6-alkyl-2-methyl-4-oxopiperidines formed from this process
was demonstrated with the total synthesis of the quinolizidine alkaloid, (+)-myrtine and the piperidine
alkaloid, (−)-solenopsin A.
Introduction
Substituted piperidines are key structural units found as com-
ponents of a wide range of natural products and pharmaceuti-
cally active compounds.1 Within this structural class, com-
pounds bearing a 2,6-trans-dialkylpiperidine core have been
isolated from a wide range of sources and found to have
important biological and medicinal properties.1 These include
(+)-myrtine (1),2 a quinolizidine alkaloid from Vaccinium myrtil-
lus (Ericaceae) and the phenylquinolizidine alkaloid (−)-lasu-
bine I (2),3 isolated from the leaves of Lagerstroemia subcostata
(Fig. 1). Natural products bearing just the 2,6-trans-dialkyl-
piperidine ring include (−)-solenopsin A (3), a component of
the venom of the fire ant Solenopsis invicta.4 As well as being
an inhibitor of phosphatidylinositol-3-kinase signalling and
angiogenesis,5 (−)-solenopsin A (3), has also been shown to
display ceramide-like biological activity with the inhibition of
the functional Akt (protein kinase B) pathway.6 Another
example is (+)-prosopinine (4), a 2,6-trans-dialkylpiperidine
alkaloid from Prosopsis africana,7 that has antihypertensive
properties and antibiotic activity against Staphyllococcus
aureus.8
As a result of their interesting and varied structures and
their significant medicinal properties, a variety of strategies for
the total syntheses of 2,6-trans-dialkylpiperidine natural pro-
ducts have been reported.9,10
One approach in accessing the 2,6-trans-dialkylpiperidine
ring system is the 6-endo-trig cyclisation11 of amine-substituted
enones.12 In 2011, we reported a one-pot, reductive amination/
6-endo-trig cyclisation that allowed the synthesis of 2,6-trans-4-
oxopipecolic acids.13 A Zimmerman–Traxler chair-like tran-
sition state in which both the side-chain and N-substituent
occupy a pseudoequatorial position was used to rationalise the
stereochemical outcome of the kinetically-controlled cyclisa-
tion (Scheme 1a). Troin and co-workers also described the
general synthesis of 2,6-trans-dialkylpiperidines by the intra-
molecular Michael-type reaction of carbamate-protected
amine-substituted enones using a combination of p-tosic acid,
ethylene glycol and trimethyl orthoformate (Scheme 1b).14
This produced the ketal derivatives of the 2,6-trans-dialkyl-4-
Fig. 1 Structures of 2,6-trans-disubstituted piperidine-containing
natural products.
†Electronic supplementary information (ESI) available: 1H and 13C NMR spectra
for all compounds. See DOI: 10.1039/c8ob01363b
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oxopiperidines that were isolated by conversion to the more
stable thioketals. Recently, we have been reinvestigating the
factors that control the stereochemical outcome of the 6-endo-
trig cyclisation of amine-substituted enones for the synthesis
of piperidine alkaloids.15,16 Herein, we now report the optimi-
sation and scope of a novel acid-mediated 6-endo-trig cyclisa-
tion for the preparation of a series of 2,6-trans-2-methyl-4-oxo-
6-alkylpiperidines (Scheme 1c). We also describe the use of
this chemistry for the total synthesis of two piperidine alka-
loids, (+)-myrtine (1) and (−)-solenopsin A (3).
Results and discussion
This study began with the synthesis of a range of amine-substi-
tuted enones. A highly eﬃcient and scalable four-step route from
commercially available N-Boc-L-aspartic acid 4-methyl ester (5)
was used to access key β-ketophosphonate ester 9 (Scheme 2).16
Chemoselective reduction of 5 via the N-hydroxysuccinimide
ester using sodium borohydride was followed by a one-step iodi-
nation of the resulting alcohol 6 using triphenylphosphine, imid-
azole and iodine.17,18 Hydrodehalogenation under basic con-
ditions19 gave β-homoalanine derivative 8. Subsequent reaction
with the lithium anion of dimethyl methylphosphonate com-
pleted the scalable, four-step synthesis of β-ketophosphonate
ester 9 in 72% overall yield.20
A small library of amine-substituted enones were prepared
via the highly stereoselective Horner–Wadsworth–Emmons
reaction of 9 with various alkyl and aryl aldehydes, using
potassium carbonate as a base, under mild conditions
(Scheme 3). This allowed the isolation of E-enones 10a–10l as
the sole products in 70–97% yield.16
Scheme 1 Methods for the synthesis of trans-2,6-disubstituted
piperidines.
Scheme 2 Synthesis of β-ketophosphonate ester 9.
Scheme 3 Synthesis of E-enones 10a–l.
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Enone 10a was then treated with an ethereal solution of
2 M hydrochloric acid in methanol at room temperature (20 °C).
After 1 h, TLC showed the formation of two new compounds.
Characterisation by 1H NMR spectroscopy identified these as
the 2,6-trans- and 2,6-cis-4-oxopiperidines (11a and 12a),
formed in a combined 58% yield and a 3 : 1 ratio, respectively
(Table 1, entry 1). Despite the acidic conditions, only trace
amounts (<5%) of the deprotected amine or the oxopiperidine
derived ketals could be detected by NMR spectroscopy. To
explore the limits of the acid mediated 6-endo-trig cyclisation,
the reaction was repeated with varying amounts of acid. Using
an excess (5 equiv.), quickly led to decomposition of the start-
ing material and the isolation of no major products (entry 2),
while using 50 mol% resulted in an incomplete reaction even
after 3 h and isolation of 11a and 12a in only 40% yield (entry
3). The temperature of the transformation was then investi-
gated in attempt to improve both the diastereoselectivity and
the overall yield. Although cooling the reaction to either 0 or
−78 °C and warming to room temperature over 2 h did result
in cleaner transformations and significantly improved yields
(entries 4 and 5), both reactions again gave 11a and 12a in a
3 : 1 ratio, respectively. Nevertheless, with the improved
eﬃciency of the cyclisation, and the straightforward separation
of the two cyclic products by column chromatography, this
allowed the isolation of the major diastereomer 11a in 49%
yield.
To provide some insight into the mechanism of the acid-
mediated 6-endo-trig cyclisation, some control experiments
were performed. Initially, the cyclisation of enone 10a over a
24 h period (Fig. 2) was analysed by 1H NMR spectroscopy. As
observed in the preparative reaction, the transformation was
complete after 2 h, giving 2,6-trans-11a and 2,6-cis-12a in a
76 : 24 ratio. After 2 h, a steady decrease in the amount of 11a
and a concurrent increase in 12a was observed, with a final
ratio of 67 : 33 in favour of 2,6-cis-product 12a (see ESI† for 1H
NMR spectra for 2–24 h). Extending the reaction time to 40 h,
showed no appreciable change in ratio (69 : 31). An additional
experiment was performed involving resubmission of diastereo-
merically pure 2,6-trans-product 11a to the acid-mediated
cyclisation conditions. Over a 6 h period, 1H NMR analysis of
the reaction mixture showed increasing epimerisation of 11a
with a final 68 : 32 ratio of 11a and 12a, respectively. These
results taken together suggest that the 2,6-trans-4-oxopipe-
ridine is the less stable, kinetic diastereomer and thus, is
formed first during the thermodynamically controlled 6-endo-
trig cyclisation. On extension of the reaction time and in the
presence of acid, a likely retro-conjugate addition reaction
results in conversion of the 2,6-trans-4-oxopiperidine to the
configurationally more stable 2,6-cis-isomer.21,22 Therefore, to
maximise selective formation of the target 2,6-trans-isomers,
short reaction times should be used. While a reaction time of
less than 2 h would likely lead to a more selective cyclisation,
the optimisation studies have shown that a 2 h reaction time is
required for full conversion. Therefore, in terms of maximising
the isolation of the target 2,6-trans-isomers, a 2 h reaction is a
good compromise.
Following optimisation of the acid-mediated cyclisation
and with some understanding of the mechanism, the scope of
the process was next investigated (Scheme 4). The 6-endo-trig
cyclisation of a range of enones 10a–10f bearing n-alkyl side-
chains typically present in piperidine alkaloid natural products
were found to be excellent substrates for this transformation,
giving a mixture of the 2,6-trans- and 2,6-cis-4-oxopiperidines
(11 and 12) in high yields (73–88%). Inspection of the 1H NMR
spectra from the crude reaction mixtures showed that the 2,6-
trans-4-oxopiperidine 11 was the major product in each case
with a diastereomeric ratio of approximately 2.5 : 1 to 3 : 1.
Formation of 2,6-trans-4-oxopiperidines 11a–11f as the major
diastereomers during the 2 h acid mediated 6-endo-trig cyclisa-
Fig. 2 Diastereomeric ratio of 11a and 12a during an extended 6-endo-
trig cyclisation reaction.
Table 1 Optimisation of the 6-endo-trig cyclisation of enone 10a a
Entry HCl (equiv.) Temp. (°C) Time (h) Yieldb (%)
1 1 20 1 58
2 5 20 1 —
3 0.5 20 3 40
4 1 0 to 20 2 75
5 1 −78 to 20 2 82
a For entries 1 and 3–5, 11a and 12a were produced in a 3 : 1 ratio as
observed by 1H NMR spectroscopy. b Isolated combined yield of 11a
and 12a.
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tion and in similar ratios irrespective of the size of the n-alkyl
side-chain provides further evidence that these are the kinetic
products from this process. For each case, the 2,6-trans-4-oxo-
piperidines 11a–11f were separated by column chromato-
graphy, allowing the isolation of these compounds in 47–55%
yields. Further examination of the scope of the cyclisation with
enones bearing functional groups (10g) and incorporating
rings (10h and 10i), gave the corresponding 2,6-trans-4-oxo-
piperidines (11g–11i) in similar diastereomeric ratios and iso-
lated yields. Limitations of the cyclisation were observed. For
example, enones 10j and 10k with a branched side-chain adja-
cent to the alkene moiety showed no diastereoselectivity.
While the cyclisation of 10j with a sec-butyl side-chain still
resulted in an eﬃcient cyclisation and the isolation of each
diastereomer in 40% yield (80% overall), the cyclisation of the
iso-propyl analogue 10k was impeded, generating the 2,6-trans-
and 2,6-cis-4-oxopiperidines 11k/12k in only 54% yield. The
other limitation discovered during this study is that enones
with a conjugated aryl side-chain (e.g. 10l) are not cyclised
under the mild conditions of this transformation.
Having developed a new approach for the synthesis of
2,6-trans-dialkyl-4-oxopiperidines, the synthetic utility of this
transformation for the facile preparation of piperidine based
natural products was next investigated (Scheme 5). Initially,
2,6-trans-4-oxopiperidine 11g bearing a 4-chlorobutyl side-
chain was converted in two steps to the quinolizidine alkaloid,
(+)-myrtine (1). While the N-Boc protecting group of 11g was
stable under the anhydrous acidic conditions of the cyclisation
reaction, facile removal was achieved under aqueous acidic
conditions. This was followed by cyclisation of the resulting
amine with the 4-chlorobutyl side-chain under basic con-
ditions, which gave (+)-myrtine (1) in 62% yield over the two
steps. 2,6-trans-4-Oxopiperidine 11f was used for a two-step
synthesis of the piperidine alkaloid, (−)-solenopsin A (3).
Treatment of 11f with 1,3-propanedithiol under Lewis acid
conditions resulted in simultaneous formation of the cyclic
dithioketal and removal of the Boc-protecting group. This gave
1,5-dithia-9-azaspiro[5.5]undecane 13 in 90% yield. Reduction
of the dithioketal using RANEY® nickel then gave (−)-solenop-
sin A (3) in 77% yield. The spectroscopic data and optical
rotations of 1 and 3 generated in this study were entirely con-
sistent with literature data.10b,14b
Conclusions
In summary, an acid-mediated 6-endo-trig cyclisation of amine-
substituted enones has been optimised for the stereoselective
synthesis of 2,6-trans-6-alkyl-2-methyl-4-oxopiperidines.
Mechanistic studies have shown that the 2,6-trans-4-oxopiperi-
dine is the kinetic product, that is then converted over time via
a possible retro-conjugate addition reaction to the configura-
tionally more stable 2,6-cis-isomer. Therefore, using a short
Scheme 4 Scope of the acid-mediated cyclisation for the preparation
of 2,6-dialkyl-4-oxopiperidines 11 and 12.
Scheme 5 Synthesis of (+)-myrtine (1) and (−)-solenopsin A (3).
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reaction time, the scope of the process was explored with a
range of amine-substituted enones bearing alkyl side-chains,
resulting in the preparation of a small library of 2,6-trans-6-
alkyl-2-methyl-4-oxopiperidines. Despite the acidic conditions,
neither Boc-group removal or acetal formation was observed,
with the Boc-protected 4-oxopiperidines isolated as the major
products in 54–95% yield. The potential of the 2,6-trans-4-oxo-
piperidines as building blocks was demonstrated with the two-
step preparation of the quinolizidine alkaloid, (+)-myrtine (1)
and the piperidine alkaloid, (−)-solenopsin A (3). Work is cur-
rently underway to investigate further synthetic applications of
this acid-mediated 6-endo-trig cyclisation reaction.
Experimental
All reagents and starting materials were obtained from com-
mercial sources and used as received. All dry solvents were pur-
ified using a solvent purification system. All reactions were per-
formed in oven-dried glassware under an atmosphere of argon
unless otherwise stated. Brine refers to a saturated solution of
sodium chloride. Flash column chromatography was per-
formed using silica gel 60 (40–63 μm). Aluminium-backed
plates pre-coated with silica gel 60F254 were used for thin layer
chromatography and were visualised with a UV lamp or by
staining with potassium permanganate. 1H NMR spectra were
recorded on a NMR spectrometer at either 400 or 500 MHz
and data are reported as follows: chemical shift in ppm relative
to tetramethylsilane or the solvent as the internal standard
(CDCl3, δ 7.26 ppm), multiplicity (s = singlet, d = doublet, t =
triplet, q = quartet, m = multiplet or overlap of nonequivalent
resonances, integration). 13C NMR spectra were recorded on a
NMR spectrometer at either 101 or 126 MHz and data are
reported as follows: chemical shift in ppm relative to tetra-
methylsilane or the solvent as internal standard (CDCl3, δ
77.0 ppm), multiplicity with respect to hydrogen (deduced
from DEPT experiments, C, CH, CH2 or CH3). IR spectra were
recorded on a FTIR spectrometer; wavenumbers are indicated
in cm−1. Mass spectra were recorded using electrospray or elec-
tron impact techniques. HRMS spectra were recorded using a
dual-focusing magnetic analyser mass spectrometer. Melting
points are uncorrected. Optical rotations were determined as
solutions irradiating with the sodium D line (λ = 589 nm)
using a polarimeter. [α]D values are given in units 10
−1
deg cm2 g−1.
Methyl (3S)-3-(tert-butoxycarbonylamino)-4-hydroxybutanoate
(6)23
To a solution of N-Boc-L-aspartic acid 4-methyl ester (5) (8.27 g,
33.5 mmol) in ethyl acetate (200 mL) at 0 °C was added
N-hydroxysuccinimide (4.24 g, 36.9 mmol). N,N-
Dicyclohexylcarbodiimide (7.05 g, 34.2 mmol) in ethyl acetate
(20 mL) was then added dropwise. The reaction mixture was
allowed to warm to room temperature and stirred for 16 h.
Once the reaction was complete, the reaction mixture was fil-
tered through Celite. The filtrate was washed with saturated
sodium carbonate solution (100 mL), brine (100 mL), dried
(MgSO4) and concentrated in vacuo. The resulting residue was
then dissolved in tetrahydrofuran (20 mL) and added dropwise
to a solution of sodium borohydride (2.03 g, 53.6 mmol) in a
mixture of tetrahydrofuran and water (7.5 : 1, 85 mL). The reac-
tion mixture was stirred for 0.1 h before quenching with satu-
rated aqueous ammonium chloride (5 mL). The reaction
mixture was extracted with dichloromethane (3 × 50 mL). The
organic fractions were combined and washed with brine
(100 mL), dried (MgSO4), filtered and concentrated in vacuo.
Purification by flash column chromatography using silica gel,
eluting with 30% ethyl acetate in dichloromethane gave
methyl (3S)-3-(tert-butoxycarbonylamino)-4-hydroxybutanoate
(6) as a colourless oil (7.03 g, 90%). [α]26D +5.6 (c 1.0, CHCl3),
lit.23 [α]23D +6.3 (c 0.5, CHCl3); δH (400 MHz, CDCl3) 1.42 (9H, s,
3 × CH3), 2.62 (2H, d, J 6.1 Hz, 2-H2), 2.82 (1H, br s, OH),
3.65–3.73 (5H, m, OCH3 and 4-H2), 3.92–4.04 (1H, m, 3-H),
5.25 (1H, br s, NH); δC (126 MHz, CDCl3) 28.4 (3 × CH3), 35.9
(CH2), 49.4 (CH), 52.0 (CH3), 64.4 (CH2), 79.9 (C), 155.9 (C),
172.4 (C); m/z (ESI) 256 (MNa+, 100%).
Methyl (3S)-3-(tert-butoxycarbonylamino)-4-iodobutanoate
(7)17
To a suspension of imidazole (4.11 g, 60.4 mmol) and tri-
phenylphosphine (11.9 g, 45.3 mmol) in a mixture of diethyl
ether and dichloromethane (2 : 1, 100 mL) at 0 °C was added
iodine (11.5 g, 45.3 mmol) in three portions over 0.5 h. After
stirring for a further 0.2 h, a solution of methyl (3S)-3-
(tert-butoxycarbonylamino)-4-hydroxybutanoate (6) (7.03 g,
30.2 mmol) in a mixture of diethyl ether and dichloromethane
(2 : 1, 50 mL) was added and the resulting mixture was stirred
for 3 h at room temperature. The reaction mixture was filtered
through Celite and the filtrate was concentrated in vacuo.
Purification by flash column chromatography using silica gel,
eluting with 30% diethyl ether in petroleum ether (40–60) gave
methyl (3S)-3-(tert-butoxycarbonylamino)-4-iodobutanoate (7)
(9.33 g, 90%) as a colourless oil. Spectroscopic data were con-
sistent with the literature.17 [α]33D +7.3 (c 1.0, CHCl3); δH
(400 MHz, CDCl3) 1.40 (9H, s, 3 × CH3), 2.60 (1H, dd, J 16.4,
6.1 Hz, 2-HH), 2.70 (1H, dd, J 16.4, 5.6 Hz, 2-HH), 3.28–3.45
(2H, m, 4-H2), 3.66 (3H, s, OCH3), 3.81–3.95 (1H, m, 3-H), 5.11
(1H, d, J 7.2 Hz, NH); δC (101 MHz, CDCl3) 11.1 (CH2), 28.5 (3 ×
CH3), 38.5 (CH2), 47.7 (CH), 52.0 (CH3), 79.9 (C), 154.7 (C),
171.1 (C); m/z (ESI) 366 (MNa+, 100%).
Methyl (3R)-3-(tert-butoxycarbonylamino)butanoate (8)24
A solution of methyl (3S)-3-(tert-butoxycarbonylamino)-4-iodo-
butanoate (7) (9.33 g, 27.2 mmol), N,N-diisopropylethylamine
(7.11 mL, 40.8 mmol) and 10% Pd/C (2.89 g) in methanol
(50 mL) were purged with hydrogen for 0.5 h. The reaction
mixture was stirred under an atmosphere of hydrogen for 18 h
at room temperature. The mixture was then filtered through
Celite and the filtrate was concentrated in vacuo. The resulting
residue was dissolved in dichloromethane (100 mL) and
washed with a saturated solution of sodium hydrogen carbon-
ate (50 mL), 1 M hydrochloric acid (50 mL), brine (50 mL),
Paper Organic & Biomolecular Chemistry
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dried over MgSO4, filtered and concentrated in vacuo to give
methyl (3R)-3-(tert-butoxycarbonylamino)butanoate (8) as a col-
ourless oil (5.87 g, 99%). Spectroscopic data were consistent
with the literature.24 [α]26D +21.5 (c 1.0, CHCl3); δH (500 MHz,
CDCl3) 1.20 (3H, d, J 6.8 Hz, 4-H3), 1.43 (9H, s, 3 × CH3), 2.47
(1H, dd, J 15.5, 6.0 Hz, 2-HH), 2.52 (1H, dd, J 15.5, 5.4 Hz,
2-HH), 3.68 (3H, s, OCH3), 4.03 (1H, br s, 3-H), 4.91 (1H, br s,
NH); δC (126 MHz, CDCl3) 20.5 (CH3), 28.4 (3 × CH3), 40.7
(CH2), 43.5 (CH), 51.6 (CH3), 79.3 (C), 155.1 (C), 172.0 (C); m/z
(ESI) 240 (MNa+, 100%).
(4R)-4-(tert-Butoxycarbonylamino)-1-(dimethyloxyphosphoryl)
pentan-2-one (9)
Dimethyl methylphosphonate (3.74 mL, 34.5 mmol) was dis-
solved in tetrahydrofuran (100 mL) and cooled to −78 °C
under an argon atmosphere. n-Butyl lithium (2.5 M, in hexane,
13.8 mL, 34.5 mmol) was added dropwise and the mixture was
stirred for 0.5 h. A solution of methyl (3R)-3-(tert-butoxycarb-
onylamino)butanoate (8) (3.00 g, 13.8 mmol) in tetrahydrofuran
(20 mL) was added dropwise. The resulting mixture was then
stirred at −78 °C for 0.5 h and allowed to warm to 0 °C over a
period of 1 h. The reaction was quenched with a saturated
aqueous solution of ammonium chloride (4 mL) and extracted
with ethyl acetate (2 × 50 mL). The combined organic layers
were combined, washed with brine (100 mL), dried (MgSO4),
filtered and concentrated in vacuo. Purification by flash
column chromatography using silica gel, eluting with 40%
ethyl acetate in dichloromethane gave (4R)-4-(tert-butoxycarb-
onylamino)-1-(dimethyloxyphosphoryl)pentan-2-one (9) (3.84 g,
90%) as a colourless oil. νmax/cm
−1 (neat) 3316 (NH), 2976
(CH), 1704 (CvO), 1700 (CvO), 1248, 1167, 1023; [α]31D +38.3
(c 1.0, CHCl3); δH (400 MHz, CDCl3) 1.17 (3H, d, J 6.7 Hz,
5-H3), 1.39 (9H, s, 3 × CH3), 2.71 (1H, dd, J 16.9, 5.9 Hz, 3-HH),
2.80 (1H, dd, J 16.9, 5.9 Hz, 3-HH), 3.03 (1H, dd, J 22.6,
13.6 Hz, 1-HH), 3.12 (1H, dd, J 22.6, 13.6 Hz, 1-HH), 3.74 (3H,
d, J 0.8 Hz, OCH3), 3.77 (3H, d, J 0.8 Hz, OCH3), 3.93–4.09 (1H,
m, 4-H), 4.92 (1H, br s, NH); δC (101 MHz, CDCl3) 20.5 (CH3),
28.3 (3 × CH3), 41.8 (d, JC–P 127.5 Hz, CH2), 43.2 (CH), 50.1
(CH2), 53.0 (d, JC–O–P 6.5 Hz, CH3), 53.1 (d, JC–O–P 6.5 Hz, CH3),
79.2 (C), 155.1 (C), 200.5 (C); m/z (ESI) 332.1225 (MNa+.
C12H24NNaO6P requires 332.1233).
(2R,5E)-2-(tert-Butoxycarbonylamino)-4-oxonona-5-ene (10a)
(4R)-4-(tert-Butoxycarbonylamino)-1-(dimethyloxyphosphoryl)
pentan-2-one (9) (0.421 g, 1.36 mmol) was dissolved in anhy-
drous acetonitrile (14 mL) and potassium carbonate (0.225 g,
1.63 mmol) was added. The mixture was stirred at room temp-
erature for 0.5 h followed by addition of butyraldehyde
(0.250 mL, 2.72 mmol). The temperature was increased to
50 °C and the mixture stirred for 72 h. The solution was then
concentrated in vacuo, redissolved in ethyl acetate (20 mL) and
washed with water (2 × 15 mL) and then brine (15 mL). The
organic layer was dried (MgSO4) and concentrated in vacuo.
Purification using a plug of silica gel, eluting with 20% ethyl
acetate in petroleum ether (40–60) gave (2R,5E)-2-(tert-butoxy-
carbonylamino)-4-oxonona-5-ene (10a) as a clear colourless oil
(0.375 g, 97%). νmax/cm
−1 (neat) 3350 (NH), 2968 (CH), 1689
(CvO), 1516, 1365, 1166, 1053, 977; [α]26D +9.3 (c 1.0, CHCl3);
δH (500 MHz, CDCl3) 0.94 (3H, t, J 7.3 Hz, 9-H3), 1.20 (3H, d,
J 6.9 Hz, 1-H3), 1.43 (9H, s, 3 × CH3), 1.46–1.55 (2H, m, 8-H2),
2.20 (2H, qd, J 6.9, 1.5 Hz, 7-H2), 2.64 (1H, dd, J 15.9, 6.5 Hz, 3-
HH), 2.86 (1H, dd, J 15.9, 4.5 Hz, 3-HH), 3.98–4.09 (1H, m,
2-H), 5.02 (1H, br s, NH), 6.09 (1H, dt, J 15.9, 1.5 Hz, 5-H), 6.86
(1H, dt, J 15.9, 6.9 Hz, 6-H); δC (126 MHz, CDCl3) 13.7 (CH3),
20.5 (CH3), 21.3 (CH2), 28.4 (3 × CH3), 34.5 (CH2), 43.7 (CH),
45.7 (CH2), 79.1 (C), 130.8 (CH), 148.2 (CH), 155.2 (C), 199.2
(C); m/z (ESI) 278.1725 (MNa+. C14H25NNaO3 requires
278.1727).
(2R,5E)-2-(tert-Butoxycarbonylamino)-4-oxodec-5-ene (10b)
The reaction was carried out according to the above procedure
for the synthesis of (2R,5E)-2-(tert-butoxycarbonylamino)-4-
oxonona-5-ene (10a) using (4R)-4-(tert-butoxycarbonylamino)-1-
(dimethyloxyphosphoryl)pentan-2-one (9) (0.100 g, 0.326
mmol) and valeraldehyde (0.070 mL, 0.652 mmol).
Purification by flash column chromatography using silica gel,
eluting with 20% diethyl ether in petroleum ether (40–60) gave
(2R,5E)-2-(tert-butoxycarbonylamino)-4-oxodec-5-ene (10b)
(0.069 g, 78%) as a colourless oil. νmax/cm
−1 (neat) 3356 (NH),
2961 (CH), 1693 (CvO), 1516, 1366, 1248, 1171, 1053; [α]20D
+6.1 (c 0.9, CHCl3); δH (400 MHz, CDCl3) 0.88 (3H, t, J 7.2 Hz,
10-H3), 1.17 (3H, d, J 6.7 Hz, 1-H3), 1.27–1.46 (13H, m, 3 × CH3,
8-H2, 9-H2), 2.19 (2H, qd, J 7.1, 1.5 Hz, 7-H2), 2.60 (1H, dd,
J 15.9, 6.6 Hz, 3-HH), 2.82 (1H, dd, J 15.9, 4.9 Hz, 3-HH),
3.94–4.07 (1H, m, 2-H), 4.95 (1H, br s, NH), 6.06 (1H, dt, J 15.9,
1.5 Hz, 5-H), 6.82 (1H, dt, J 15.9, 7.1 Hz, 6-H); δC (101 MHz,
CDCl3) 13.7 (CH3), 20.5 (CH3), 22.2 (CH2), 28.4 (3 × CH3), 30.1
(CH2), 32.1 (CH2), 43.7 (CH), 45.7 (CH2), 79.1 (C), 130.6 (CH),
148.4 (CH), 155.1 (C), 199.0 (C); m/z (ESI) 292.1890 (MNa+.
C15H27NNaO3 requires 292.1889).
(2R,5E)-2-(tert-Butoxycarbonylamino)-4-oxoundec-5-ene (10c)
The reaction was carried out according to the above procedure
for the synthesis of (2R,5E)-2-(tert-butoxycarbonylamino)-4-
oxonona-5-ene (10a) using (4R)-4-(tert-butoxycarbonylamino)-1-
(dimethyloxyphosphoryl)pentan-2-one (9) (0.047 g, 0.151
mmol) and hexanal (0.037 mL, 0.303 mmol). Purification by
flash column chromatography using silica gel, eluting with
20% diethyl ether in petroleum ether (40–60) gave (2R,5E)-2-
(tert-butoxycarbonylamino)-4-oxoundec-5-ene (10c) as a colour-
less oil (0.035 g, 81%). νmax/cm
−1 (neat) 3341 (NH), 2928 (CH),
1694 (CvO), 1516, 1366, 1173, 1053; [α]24D +5.6 (c 0.7, CHCl3);
δH (400 MHz, CDCl3) 0.89 (3H, t, J 6.9 Hz, 11-H3), 1.20 (3H, d,
J 6.7 Hz, 1-H3), 1.24–1.36 (4H, m, 9-H2 and 10-H2), 1.40–1.52
(11H, m, 8-H2 and 3 × CH3), 2.14 (2H, qd, J 7.1, 1.4 Hz, 7-H2),
2.63 (1H, dd, J 15.9, 6.5 Hz, 3-HH), 2.85 (1H, dd, J 15.9, 4.6 Hz,
3-HH), 3.95–4.07 (1H, m, 2-H), 4.94 (1H, br s, NH), 6.08 (1H,
dt, J 15.8, 1.4 Hz, 5-H), 6.85 (1H, dt, J 15.8, 7.1 Hz, 6-H); δC
(101 MHz, CDCl3) 14.1 (CH3), 20.6 (CH3), 22.6 (CH2), 27.9
(CH2), 28.6 (3 × CH3), 31.5 (CH2), 32.6 (CH2), 43.9 (CH), 45.8
(CH2), 79.3 (C), 130.7 (CH), 148.7 (CH), 155.3 (C), 199.3 (C);
m/z (ESI) 306.2039 (MNa+. C16H29NNaO3 requires 306.2040).
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(2R,5E)-2-(tert-Butoxycarbonylamino)-4-oxotetradec-5-ene
(10d)
The reaction was carried out according to the above procedure
for the synthesis of (2R,5E)-2-(tert-butoxycarbonylamino)-4-
oxonona-5-ene (10a) using (4R)-4-(tert-butoxycarbonylamino)-1-
(dimethyloxyphosphoryl)pentan-2-one (9) (0.129 g, 0.416
mmol) and nonanal (0.143 mL, 0.832 mmol). Purification by
flash column chromatography using silica gel, eluting with
30% diethyl ether in petroleum ether (40–60) gave (2R,5E)-2-
(tert-butoxycarbonylamino)-4-oxotetradec-5-ene (10d) as a col-
ourless oil (0.098 g, 72%). νmax/cm
−1 (neat) 3352 (NH), 2924
(CH), 1694 (CvO), 1501, 1366, 1246, 1169, 1053; [α]29D +6.5
(c 0.8, CHCl3); δH (400 MHz, CDCl3) 0.87 (3H, t, J 6.9 Hz,
14-H3), 1.19 (3H, d, J 6.7 Hz, 1-H3), 1.22–1.35 (10H, m, 9-H2,
10-H2, 11-H2, 12-H2 and 13-H2), 1.38–1.50 (11H, m, 8-H2 and 3
× CH3), 2.20 (2H, qd, J 7.0, 1.5 Hz, 7-H2), 2.62 (1H, dd, J 15.9,
6.5 Hz, 3-HH), 2.85 (1H, dd, J 15.9, 4.8 Hz, 3-HH), 3.95–4.09
(1H, m, 2-H), 4.95 (1H, br s, NH), 6.07 (1H, dt, J 15.9, 1.5 Hz,
5-H), 6.84 (1H, dt, J 15.9, 7.0 Hz, 6-H); δC (101 MHz, CDCl3)
14.1 (CH3), 20.5 (CH3), 22.7 (CH2), 28.1 (CH2), 28.4 (3 × CH3),
29.2 (2 × CH2), 29.3 (CH2), 31.8 (CH2), 32.5 (CH2), 43.8 (CH),
45.7 (CH2), 79.2 (C), 130.6 (CH), 148.5 (CH), 155.2 (C), 199.1
(C); m/z (ESI) 348.2498 (MNa+. C19H35NNaO3 requires
348.2509).
(2R,5E)-2-(tert-Butoxycarbonylamino)-4-oxopentadec-5-ene
(10e)
The reaction was carried out according to the above procedure
for the synthesis of (2R,5E)-2-(tert-butoxycarbonylamino)-4-
oxonona-5-ene (10a) using (4R)-4-(tert-butoxycarbonylamino)-1-
(dimethyloxyphosphoryl)pentan-2-one (9) (0.405 g, 1.31 mmol)
and decanal (0.500 mL, 2.62 mmol) for 96 h. Purification by
flash column chromatography using silica gel, eluting with
30% diethyl ether in petroleum ether (40–60) gave (2R,5E)-2-
(tert-butoxycarbonylamino)-4-oxopentadec-5-ene (10e) (0.345 g,
78%) as a colourless oil. νmax/cm
−1 (neat) 3327 (NH), 2958
(CH), 1693 (CvO), 1365, 1170, 1053; [α]25D +4.2 (c 1.0, CHCl3);
δH (400 MHz, CDCl3) 0.88 (3H, t, J 6.3 Hz, 15-H3), 1.20 (3H, d,
J 6.7 Hz, 1-H3), 1.23–1.34 (12H, m, 9-H2, 10-H2, 11-H2, 12-H2,
13-H2 and 14-H2), 1.39–1.50 (11H, m, 8-H2 and 3 × CH3), 2.20
(2H, q, J 7.0 Hz, 7-H2), 2.63 (1H, dd, J 15.7, 6.6 Hz, 3-HH), 2.85
(1H, dd, J 15.7, 4.5 Hz, 3-HH), 3.96–4.08 (1H, m, 2-H), 4.95
(1H, br s, NH), 6.08 (1H, d, J 15.6 Hz, 5-H), 6.85 (1H, dt, J 15.6,
7.0 Hz, 6-H); δC (126 MHz, CDCl3) 14.1 (CH3), 20.5 (CH3), 22.7
(CH2), 28.1 (CH2), 28.4 (3 × CH3), 29.2 (CH2), 29.3 (CH2), 29.4
(CH2), 29.5 (CH2), 31.9 (CH2), 32.5 (CH2), 43.7 (CH), 45.7
(CH2), 79.2 (C), 130.6 (CH), 148.5 (CH), 155.2 (C), 199.2 (C);
m/z (ESI) 362.2649 (MNa+. C20H37NNaO3 requires 362.2666).
(2R,5E)-2-(tert-Butoxycarbonylamino)-4-oxoheptadec-5-ene
(10f)
The reaction was carried out according to the above procedure
for the synthesis of (2R,5E)-2-(tert-butoxycarbonylamino)-4-
oxonona-5-ene (10a) using (4R)-4-(tert-butoxycarbonylamino)-1-
(dimethyloxyphosphoryl)pentan-2-one (9) (0.750 g, 2.42 mmol)
and dodecanal (1.08 mL, 4.85 mmol). Purification by flash
column chromatography using silica gel, eluting with 30%
diethyl ether in petroleum ether (40–60) gave (2R,5E)-2-(tert-
butoxycarbonylamino)-4-oxoheptadec-5-ene (10f ) as a colour-
less oil (0.734 g, 83%). νmax/cm
−1 (neat) 3354 (NH), 2925 (CH),
1694 (CvO), 1515, 1366, 1248, 1172, 1053; [α]22D +4.8 (c 1.0,
CHCl3); δH (400 MHz, CDCl3) 0.87 (3H, t, J 6.8 Hz, 17-H3), 1.19
(3H, d, J 6.8 Hz, 1-H3), 1.22–1.36 (16H, m, 9-H2, 10-H2, 11-H2,
12-H2, 13-H2, 14-H2, 15-H2 and 16-H2), 1.38–1.50 (11H, m,
8-H2, 3 × CH3), 2.20 (2H, qd, J 7.1, 1.4 Hz, 7-H2), 2.63 (1H, dd,
J 15.9, 6.6 Hz, 3-HH), 2.85 (1H, dd, J 15.9, 4.7 Hz, 3-HH),
3.93–4.09 (1H, m, 2-H), 4.96 (1H, br s, NH), 6.07 (1H, dt, J 15.8,
1.4 Hz, 5-H), 6.85 (1H, dt, J 15.8, 7.1 Hz, 6-H); δC (101 MHz,
CDCl3) 14.3 (CH3), 20.6 (CH3), 22.8 (CH2), 28.2 (CH2), 28.6 (3 ×
CH3), 29.3 (CH2), 29.5 (2 × CH2), 29.7 (CH2), 29.8 (2 × CH2),
32.0 (CH2), 32.7 (CH2), 43.8 (CH), 45.8 (CH2), 79.3 (C), 130.7
(CH), 148.7 (CH), 155.3 (C), 199.3 (C); m/z (ESI) 390.2985
(MNa+. C22H41NNaO3 requires 390.2979).
(2R,5E)-2-(tert-Butoxycarbonylamino)-10-chloro-4-oxodec-5-ene
(10g)
The reaction was carried out according to the above procedure
for the synthesis of (2R,5E)-2-(tert-butoxycarbonylamino)-4-
oxonona-5-ene (10a) using (4R)-4-(tert-butoxycarbonylamino)-1-
(dimethyloxyphosphoryl)pentan-2-one (9) (0.114 g, 0.367
mmol) and 5-chloropentanal (0.089 g, 0.735 mmol) for 96 h.
Purification by flash column chromatography using silica gel,
eluting with 30% diethyl ether in petroleum ether (40–60) gave
(2R,5E)-2-(tert-butoxycarbonylamino)-10-chloro-4-oxodec-5-ene
(10g) as a colourless oil (0.098 g, 88%). νmax/cm
−1 (neat) 3357
(NH), 2977 (CH), 1693 (CvO), 1663 (CvO), 1510, 1366, 1247,
1167, 1053; [α]22D +4.7 (c 1.0, CHCl3); δH (400 MHz, CDCl3) 1.19
(3H, d, J 6.8 Hz, 1-H3), 1.42 (9H, s, 3 × CH3), 1.57–1.67 (2H, m,
8-H2), 1.74–1.88 (2H, m, 9-H2), 2.25 (2H, qd, J 6.9, 1.5 Hz,
7-H2), 2.62 (1H, dd, J 15.9, 6.6 Hz, 3-HH), 2.85 (1H, dd, J 15.9,
4.7 Hz, 3-HH), 3.54 (2H, t, J 6.5 Hz, 10-H2), 3.94–4.08 (1H, m,
2-H), 4.94 (1H, br s, NH), 6.09 (1H, dt, J 15.9, 1.5 Hz, 5-H), 6.83
(1H, dt, J 15.9, 6.9 Hz, 6-H); δC (101 MHz, CDCl3) 20.6 (CH3),
25.4 (CH2), 28.5 (3 × CH3), 31.7 (CH2), 32.0 (CH2), 43.8 (CH),
44.7 (CH2), 46.0 (CH2), 79.3 (C), 131.0 (CH), 147.2 (CH), 155.3
(C), 199.0 (C); m/z (ESI) 326.1484 (MNa+. C15H26
35ClNNaO3
requires 326.1493).
(2R,5E)-2-(tert-Butoxycarbonylamino)-8-cyclohexyl-4-oxooct-5-
ene (10h)
The reaction was carried out according to the above procedure
for the synthesis of (2R,5E)-2-(tert-butoxycarbonylamino)-4-
oxonona-5-ene (10a) using (4R)-4-(tert-butoxycarbonylamino)-1-
(dimethyloxyphosphoryl)pentan-2-one (9) (0.044 g, 0.144
mmol) and 3-cyclohexylpropanal (0.040 g, 0.288 mmol).
Purification by flash column chromatography using silica gel,
eluting with 30% diethyl ether in petroleum ether (40–60) gave
(2R,5E)-2-(tert-butoxycarbonylamino)-8-cyclohexyl-4-oxodec-5-ene
(10h) as a colourless oil (0.037 g, 79%). νmax/cm
−1 (neat) 3341
(NH), 2924 (CH), 1694 (CvO), 1512, 1366, 1246, 1169, 1053;
[α]24D +5.1 (c 0.9, CHCl3); δH (400 MHz, CDCl3) 0.80–0.96 (2H,
Paper Organic & Biomolecular Chemistry
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m, CH2), 1.09–1.28 (8H, m, 1-H3, 8-CH, 2 × CH2), 1.34 (2H, q,
J 6.9 Hz, 8-H2), 1.43 (9H, s, 3 × CH3), 1.60–1.78 (4H, m, 2 ×
CH2), 2.22 (2H, qd, J 6.9, 1.5 Hz, 7-H2), 2.63 (1H, dd, J 15.8, 6.6
Hz, 3-HH), 2.85 (1H, dd, J 15.8, 4.8 Hz, 3-HH), 3.97–4.07 (1H,
m, 2-H), 4.94 (1H, br s, NH), 6.08 (1H, dd, J 15.9, 1.5 Hz, 5-H),
6.85 (1H, dd, J 15.9, 6.9 Hz, 6-H); δC (101 MHz, CDCl3) 20.7
(CH3), 26.4 (2 × CH2), 26.7 (CH2), 28.6 (3 × CH3), 30.1 (CH2),
33.3 (2 × CH2), 35.8 (CH2), 37.3 (CH), 43.9 (CH), 45.8 (CH2),
79.3 (C), 130.6 (CH), 149.0 (CH), 155.3 (C), 199.3 (C); m/z (ESI)
346.2343 (MNa+. C19H33NNaO3 requires 346.2353).
(2R,5E)-2-(tert-Butoxycarbonylamino)-4-oxo-8-phenyloct-5-ene
(10i)
The reaction was carried out according to the above procedure
for the synthesis of (2R,5E)-2-(tert-butoxycarbonylamino)-4-
oxonona-5-ene (10a) using (4R)-4-(tert-butoxycarbonylamino)-1-
(dimethyloxyphosphoryl)pentan-2-one (9) (0.349 g, 1.13 mmol)
and hydrocinnamaldehyde (0.300 mL, 2.26 mmol) for 48 h.
Purification by flash column chromatography using silica gel,
eluting with 20% ethyl acetate in petroleum ether (40–60)
gave (2R,5E)-2-(tert-butoxycarbonylamino)-4-oxo-8-phenyloct-5-
ene (10i) (0.288 g, 80%) as a pale yellow oil. νmax/cm
−1 (neat)
3353 (NH), 2976 (CH), 1692 (CvO), 1496 (CvC), 1247, 1221,
1054; [α]23D +4.1 (c 1.0, CHCl3); δH (400 MHz, CDCl3) 1.17 (3H,
d, J 6.7 Hz, 1-H3), 1.43 (9H, s, 3 × CH3), 2.53 (2H, q, J 6.8 Hz,
7-H2), 2.60 (1H, dd, J 15.7, 7.8 Hz, 3-HH), 2.77 (2H, t, J 6.8 Hz,
8-H2), 2.84 (1H, dd, J 15.7, 4.5 Hz, 3-HH), 3.95–4.08 (1H, m,
2-H), 4.99 (1H, br s, NH), 6.09 (1H, d, J 15.9 Hz, 5-H), 6.87 (1H,
dt, J 15.9, 6.8 Hz, 6-H), 7.14–7.23 (3H, m, 3 × ArH), 7.25–7.32
(2H, m, 2 × ArH); δC (101 MHz, CDCl3) 20.5 (CH3), 28.5 (3 ×
CH3), 34.2 (CH2), 34.4 (CH2), 43.7 (CH), 45.9 (CH2), 79.2 (C),
126.3 (CH), 128.4 (2 × CH), 128.6 (2 × CH), 131.1 (CH), 140.7
(C), 147.0 (CH), 155.2 (C), 199.0 (C); m/z (ESI) 340.1868 (MNa+.
C19H27NNaO3 requires 340.1883).
(2R,5E)-2-(tert-Butoxycarbonylamino)-8-methyl-4-oxonon-5-ene
(10j)
The reaction was carried out according to the above procedure
for the synthesis of (2R,5E)-2-(tert-butoxycarbonylamino)-4-
oxonona-5-ene (10a) using (4R)-4-(tert-butoxycarbonylamino)-1-
(dimethyloxyphosphoryl)pentan-2-one (9) (0.141 g, 0.455 mmol)
and isovaleraldehyde (0.097 mL, 0.910 mmol). Purification by
flash column chromatography using silica gel, eluting with
40% diethyl ether in petroleum ether (40–60) gave (2R,5E)-2-
(tert-butoxycarbonylamino)-8-methyl-4-oxonon-5-ene (10j)
(0.080 g, 70%) as a colourless oil. νmax/cm
−1 (neat) 3356 (NH),
2963 (CH), 1690 (CvO), 1504, 1366, 1165, 1250, 1049; [α]29D
+7.5 (c 0.5, CHCl3); δH (400 MHz, CDCl3) 0.91 (6H, d, J 6.7 Hz,
8-CH3 and 9-H3), 1.18 (3H, d, J 6.8 Hz, 1-H3), 1.41 (9H, s,
3 × CH3), 1.67–1.83 (1H, m, 8-H), 2.09 (2H, td, J 7.5, 1.3 Hz,
7-H2), 2.62 (1H, dd, J 15.9, 6.6 Hz, 3-HH), 2.84 (1H, dd, J 15.9,
4.8 Hz, 3-HH), 3.94–4.08 (1H, m, 2-H), 4.95 (1H, br s, NH), 6.06
(1H, dt, J 15.7, 1.3 Hz, 5-H), 6.81 (1H, dt, J 15.7, 7.5, 6-H);
δC (101 MHz, CDCl3) 20.6 (CH3), 22.5 (2 × CH3), 28.0 (CH), 28.5
(3 × CH3), 41.9 (CH2), 43.9 (CH), 45.9 (CH2), 79.3 (C), 131.8
(CH), 147.3 (CH), 155.3 (C), 199.1 (C); m/z (ESI) 292.1873
(MNa+. C15H27NNaO3 requires 292.1883).
(2R,5E)-2-(tert-Butoxycarbonylamino)-7-methyl-4-oxooct-5-ene
(10k)
The reaction was carried out according to the above procedure
for the synthesis of (2R,5E)-2-(tert-butoxycarbonylamino)-4-
oxonona-5-ene (10a) using (4R)-4-(tert-butoxycarbonylamino)-1-
(dimethyloxyphosphoryl)pentan-2-one (9) (0.160 g, 0.517 mmol)
and isobutyraldehyde (0.095 mL, 1.04 mmol). Purification by
flash column chromatography using silica gel, eluting with
30% diethyl ether in petroleum ether (40–60) gave (2R,5E)-
2-(tert-butoxycarbonylamino)-7-methyl-4-oxooct-5-ene (10k)
(0.112 g, 85%) as a colourless oil. νmax/cm
−1 (neat) 3356 (NH),
2970 (CH), 1690 (CvO), 1512, 1366, 1250, 1165, 1049; [α]29D
+9.4 (c 1.2, CHCl3); δH (400 MHz, CDCl3) 1.02 (6H, d, J 6.8 Hz,
7-CH3 and 8-H3), 1.15 (3H, d, J 6.8 Hz, 1-H3), 1.38 (9H, s, 3 ×
CH3), 2.35–2.47 (1H, m, 7-H), 2.60 (1H, dd, J 16.0, 6.6 Hz,
3-HH), 2.81 (1H, dd, J 16.0, 4.8 Hz, 3-HH), 3.90–4.05 (1H, m,
2-H), 4.97 (1H, br s, NH), 5.99 (1H, dd, J 16.0, 1.2 Hz, 5-H),
6.76 (1H, dd, J 16.0, 6.7 Hz, 6-H); δC (101 MHz, CDCl3) 20.6
(CH3), 21.3 (2 × CH3), 28.5 (3 × CH3), 31.2 (CH), 43.7 (CH), 45.8
(CH2), 79.1 (C), 127.8 (CH), 154.3 (CH), 155.2 (C), 199.4 (C);
m/z (ESI) 278.1722 (MNa+. C14H25NNaO3 requires 278.1727).
(2R,5E)-2-(tert-Butoxycarbonylamino)-4-oxo-6-phenylhex-5-ene
(10l)
The reaction was carried out according to the above procedure
for the synthesis of (2R,5E)-2-(tert-butoxycarbonylamino)-4-
oxonona-5-ene (10a) using (4R)-4-(tert-butoxycarbonylamino)-1-
(dimethyloxyphosphoryl)pentan-2-one (9) (0.251 g, 0.810
mmol) and benzaldehyde (0.160 mL, 1.62 mmol) for 48 h.
Purification by flash column chromatography using silica gel,
eluting with 20% ethyl acetate in petroleum ether (40–60)
gave (2R,5E)-2-(tert-butoxycarbonylamino)-4-oxo-6-phenylhex-5-
ene (10l) (0.227 g, 97%) as a white solid. Mp 59–62 °C;
νmax/cm
−1 (neat) 3345 (NH), 2976 (CH), 1687 (CvO), 1655
(CvO), 1608 (CvC), 1495, 1365, 1247, 1166; [α]23D +10.0 (c 1.0,
CHCl3); δH (400 MHz, CDCl3) 1.25 (3H, d, J 6.8 Hz, 1-H3), 1.43
(9H, s, 3 × CH3), 2.77 (1H, dd, J 15.8, 6.8 Hz, 3-HH), 3.00 (1H,
dd, J 15.8, 4.6 Hz, 3-HH), 4.05–4.18 (1H, m, 2-H), 5.04 (1H, br
s, NH), 6.73 (1H, d, J 16.2 Hz, 5-H), 7.36–7.41 (3H, m, 3 × ArH),
7.52–7.54 (2H, m, 2 × ArH), 7.56 (1H, d, J 16.2 Hz, 6-H);
δC (101 MHz, CDCl3) 20.6 (CH3), 28.4 (3 × CH3), 43.8 (CH), 46.6
(CH2), 79.2 (C), 126.4 (CH), 128.4 (2 × CH), 129.0 (2 × CH),
130.6 (CH), 134.4 (C), 143.2 (CH), 155.2 (C), 198.9 (C); m/z (ESI)
312.1558 (MNa+. C17H23NNaO3 requires 312.1570).
tert-Butyl (2R,6R)-2-methyl-4-oxo-6-propylpiperidine-1-
carboxylate (11a)
(2R,5E)-2-(tert-Butoxycarbonylamino)-4-oxonona-5-ene (10a)
(0.0756 g, 0.296 mmol) was dissolved in methanol (7.4 mL)
and cooled to −78 °C. 2 M hydrochloric acid in diethyl ether
(0.148 mL, 0.296 mmol) was added and the solution stirred at
this temperature for 1 h and, then at room temperature for
1 h. Upon completion, the mixture was concentrated in vacuo.
Organic & Biomolecular Chemistry Paper
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Purification by flash column chromatography using silica gel,
eluting with 30% diethyl ether in petroleum ether (40–60) gave
tert-butyl (2R,6R)-2-methyl-4-oxo-6-propylpiperidine-1-carboxy-
late (11a) (0.0369 g, 49%) as a colourless oil. νmax/cm
−1 (neat)
2964 (CH), 1726 (CvO), 1688 (CvO), 1389, 1174, 1101; [α]22D
+151.7 (c 1.0, CHCl3); δH (400 MHz, CDCl3) 0.90 (3H, t, J 7.2
Hz, 3″-H3), 1.20–1.39 (6H, m, 1′-H3, 1″-HH and 2″-H2), 1.49
(9H, s, 3 × CH3), 1.65–1.78 (1H, m, 1″-HH), 2.35 (1H, dd, J 17.7,
2.0 Hz, 3-HH), 2.52 (1H, dd, J 17.9, 2.0 Hz, 5-HH), 2.70 (1H,
ddd, J 17.9, 6.3, 1.4 Hz, 5-HH), 2.81 (1H, dd, J 17.7, 6.3 Hz,
3-HH), 4.10–4.22 (1H, m, 6-H), 4.29–4.40 (1H, m, 2-H);
δC (101 MHz, CDCl3) 14.0 (CH3), 20.1 (CH2), 22.9 (CH3), 28.6 (3
× CH3), 39.4 (CH2), 41.4 (CH2), 44.7 (CH2), 46.6 (CH), 51.0
(CH), 80.0 (C), 154.7 (C), 208.3 (C); m/z (ESI) 278.1730 (MNa+.
C14H25NNaO3 requires 278.1727).
tert-Butyl (2R,6R)-6-butyl-2-methyl-4-oxopiperidine-1-
carboxylate (11b)
The reaction was carried out according to the above procedure
for the synthesis of tert-butyl (2R,6R)-2-methyl-4-oxo-6-propyl-
piperidine-1-carboxylate (11a) using (2R,5E)-2-(tert-butoxy-
carbonylamino)-4-oxodec-5-ene (10b) (0.0616 g, 0.229 mmol).
Purification by flash column chromatography using silica gel,
eluting with 20% diethyl ether in petroleum ether (40–60) gave
tert-butyl (2R,6R)-6-butyl-2-methyl-4-oxopiperidine-1-carboxy-
late (11b) (0.0320 g, 52%) as a colourless oil. νmax/cm
−1 (neat)
2961 (CH), 1727 (CvO), 1691 (CvO), 1390, 1175; [α]20D +131.8
(c 0.2, CHCl3); δH (400 MHz, CDCl3) 0.88 (3H, t, J 7.0 Hz,
4″-H3), 1.17–1.39 (8H, m, 1′-H3, 1″-HH, 2″-H2 and 3″-H2), 1.49
(9H, s, 3 × CH3), 1.68–1.86 (1H, m, 1″-HH), 2.35 (1H, dd, J 17.7,
1.9 Hz, 3-HH), 2.52 (1H, dd, J 17.9, 2.1 Hz, 5-HH), 2.72 (1H,
ddd, J 17.9, 6.2, 1.4 Hz, 5-HH), 2.81 (1H, dd, J 17.7, 6.4 Hz,
3-HH), 4.04–4.24 (1H, m, 6-H), 4.30–4.44 (1H, m, 2-H);
δC (101 MHz, CDCl3) 14.0 (CH3), 22.5 (CH2), 22.7 (CH3), 28.5
(3 × CH3), 28.9 (CH2), 36.9 (CH2), 41.3 (CH2), 44.6 (CH2), 46.5
(CH), 51.2 (CH), 79.9 (C), 154.6 (C), 208.0 (C); m/z (ESI)
292.1886 (MNa+. C15H27NNaO3 requires 292.1889).
tert-Butyl (2R,6R)-2-methyl-4-oxo-6-pentylpiperidine-1-
carboxylate (11c)
The reaction was carried out according to the above procedure
for the synthesis of tert-butyl (2R,6R)-2-methyl-4-oxo-6-propyl-
piperidine-1-carboxylate (11a) using (2R,5E)-2-(tert-butoxycar-
bonylamino)-4-oxoundec-5-ene (10c) (0.0852 g, 0.301 mmol).
Purification by flash column chromatography using silica gel,
eluting with 20% diethyl ether in petroleum ether (40–60) gave
tert-butyl (2R,6R)-2-methyl-4-oxo-6-pentylpiperidine-1-carboxy-
late (11c) (0.0402 g, 47%) as a colourless oil. νmax/cm
−1 (neat)
2932 (CH), 1728 (CvO), 1690 (CvO), 1366, 1173; [α]25D +139.9
(c 0.4, CHCl3); δH (500 MHz, CDCl3) 0.86 (3H, t, J 6.8 Hz,
5″-H3), 1.17–1.35 (10H, m, 1′-H3, 1″-HH, 2″-H2, 3″-H2 and 4″-H2),
1.49 (9H, s, 3 × CH3), 1.67–1.80 (1H, m, 1″-HH), 2.36 (1H, dd,
J 17.7, 1.9 Hz, 3-HH), 2.53 (1H, dd, J 17.9, 2.0 Hz, 5-HH), 2.71
(1H, ddd, J 17.9, 6.2, 1.3 Hz, 5-HH), 2.80 (1H, dd, J 17.7, 6.4
Hz, 3-HH), 4.05–4.22 (1H, m, 6-H), 4.25–4.40 (1H, m, 2-H); δC
(126 MHz, CDCl3) 14.1 (CH3), 22.7 (CH2), 22.9 (CH3), 26.6
(CH2), 28.6 (3 × CH3), 31.7 (CH2), 37.3 (CH2), 41.4 (CH2), 44.7
(CH2), 46.6 (CH), 51.3 (CH), 80.0 (C), 154.7 (C), 208.3 (C); m/z
(ESI) 306.2034 (MNa+. C16H29NNaO3 requires 306.2040).
tert-Butyl (2R,6R)-2-methyl-6-octyl-4-oxopiperidine-1-
carboxylate (11d)
The reaction was carried out according to the above procedure
for the synthesis of tert-butyl (2R,6R)-2-methyl-4-oxo-6-propyl-
piperidine-1-carboxylate (11a) using (2R,5E)-2-(tert-butoxy-
carbonylamino)-4-oxotetraadec-5-ene (10d) (0.0977 g, 0.300
mmol). Purification by flash column chromatography using
silica gel, eluting with 20% diethyl ether in petroleum ether
(40–60) gave tert-butyl (2R,6R)-2-methyl-6-octyl-4-oxopiperidine-
1-carboxylate (11d) (0.0495 g, 51%) as a colourless oil. νmax/
cm−1 (neat) 2924 (CH), 1728 (CvO), 1690 (CvO), 1366, 1172;
[α]30D +158.2 (c 0.6, CHCl3); δH (400 MHz, CDCl3) 0.87 (3H, t,
J 6.9 Hz, 8″-H3), 1.15–1.35 (16H, m, 1′-H3, 1″-HH, 2″-H2, 3″-H2,
4″-H2, 5″-H2, 6″-H2, and 7″-H2), 1.49 (9H, s, 3 × CH3), 1.65–1.80
(1H, m, 1″-HH), 2.36 (1H, dd, J 17.8, 1.9 Hz, 3-HH), 2.53 (1H,
dd, J 17.9, 2.0 Hz, 5-HH), 2.72 (1H, ddd, J 17.9, 6.2, 1.3 Hz,
5-HH), 2.81 (1H, dd, J 17.8, 6.4 Hz, 3-HH), 4.05–4.20 (1H, m,
6-H), 4.28–4.45 (1H, m, 2-H); δC (101 MHz, CDCl3) 14.2 (CH3),
22.8 (CH2), 22.9 (CH3), 26.9 (CH2), 28.6 (3 × CH3), 29.3 (CH2),
29.6 (CH2), 29.7 (CH2), 32.0 (CH2), 37.3 (CH2), 41.4 (CH2), 44.7
(CH2), 46.6 (CH), 51.3 (CH), 80.0 (C), 154.7 (C), 208.3 (C); m/z
(ESI) 348.2515 (MNa+. C19H35NNaO3 requires 348.2509).
tert-Butyl (2R,6R)-2-methyl-6-nonyl-4-oxopiperidine-1-
carboxylate (11e)
The reaction was carried out according to the above procedure
for the synthesis of tert-butyl (2R,6R)-2-methyl-4-oxo-6-propyl-
piperidine-1-carboxylate (11a) using (2R,5E)-2-(tert-butoxycar-
bonylamino)-4-oxopentadec-5-ene (10e) (0.0996 g, 0.148 mmol).
Purification by flash column chromatography using silica gel,
eluting with 20% diethyl ether in petroleum ether (40–60) gave
tert-butyl (2R,6R)-2-methyl-6-nonyl-4-oxopiperidine-1-carboxy-
late (11e) (0.0444 g, 55%) as a colourless oil. νmax/cm
−1 (neat)
2925 (CH), 1726 (CvO), 1691 (CvO), 1389, 1175, 1094; [α]23D
+102.4 (c 1.1, CHCl3); δH (400 MHz, CDCl3) 0.87 (3H, t,
J 6.8 Hz, 9″-H3), 1.16–1.36 (18H, m, 1′-H3, 1″-HH, 2″-H2, 3″-H2,
4″-H2, 5″-H2, 6″-H2, 7″-H2 and 8″-H2), 1.49 (9H, s, 3 × CH3),
1.68–1.80 (1H, m, 1″-HH), 2.35 (1H, dd, J 17.7, 1.8 Hz, 3-HH),
2.52 (1H, dd, J 18.0, 1.8 Hz, 5-HH), 2.71 (1H, ddd, J 18.0, 5.5,
0.8 Hz, 5-HH), 2.80 (1H, dd, J 17.7, 6.4 Hz, 3-HH), 4.08–4.19
(1H, m, 6-H), 4.29–4.40 (1H, m, 2-H); δC (101 MHz, CDCl3) 14.1
(CH3), 22.7 (CH2), 22.7 (CH3), 26.8 (CH2), 28.5 (3 × CH3), 29.3
(CH2), 29.4 (CH2), 29.5 (CH2), 29.6 (CH2), 31.9 (CH2), 37.2
(CH2), 41.3 (CH2), 44.6 (CH2), 46.5 (CH), 51.2 (CH), 79.9 (C),
154.5 (C), 208.2 (C); m/z (ESI) 362.2662 (MNa+. C20H37NNaO3
requires 362.2666).
tert-Butyl (2R,6R)-2-methyl-4-oxo-6-undecylpiperidine-1-
carboxylate (11f)
The reaction was carried out according to the above procedure
for the synthesis of tert-butyl (2R,6R)-2-methyl-4-oxo-6-propyl-
piperidine-1-carboxylate (11a) using (2R,5E)-2-(tert-butoxycar-
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bonylamino)-4-oxoheptadec-5-ene (10f ) (0.113 g, 0.307 mmol).
Purification by flash column chromatography using silica gel,
eluting with 20% diethyl ether in petroleum ether (40–60) gave
tert-butyl (2R,6R)-2-methyl-4-oxo-6-undecylpiperidine-1-carbox-
ylate (11f ) (0.0551 g, 49%) as a colourless oil. νmax/cm
−1 (neat)
2924 (CH), 1726 (CvO), 1691 (CvO), 1389, 1174, 1095; [α]24D
+92.7 (c 1.0, CHCl3); δH (400 MHz, CDCl3) 0.88 (3H, t, J 6.9 Hz,
11″-H3), 1.18–1.38 (22H, m, 1′-H3, 1″-HH, 2″-H2, 3″-H2, 4″-H2,
5″-H2, 6″-H2, 7″-H2, 8″-H2, 9″-H2 and 10″-H2), 1.49 (9H, s, 3 ×
CH3), 1.66–1.80 (1H, m, 1″-HH), 2.36 (1H, dd, J 17.7, 1.9 Hz,
3-HH), 2.53 (1H, dd, J 17.9, 2.0 Hz, 5-HH), 2.71 (1H, ddd,
J 17.9, 6.2, 1.3 Hz, 5-HH), 2.81 (1H, dd, J 17.7, 6.5 Hz, 3-HH),
4.07–4.23 (1H, m, 6-H), 4.27–4.43 (1H, m, 2-H); δC (101 MHz,
CDCl3) 14.3 (CH3), 22.8 (CH2), 22.9 (CH3), 26.9 (CH2), 28.7 (3 ×
CH3), 29.5 (CH2), 29.6 (CH2), 29.7 (3 × CH2), 29.8 (CH2) 32.1
(CH2), 37.3 (CH2), 41.4 (CH2), 44.7 (CH2), 46.6 (CH), 51.3 (CH),
80.0 (C), 154.7 (C), 208.3 (C); m/z (ESI) 390.2963 (MNa+.
C22H41NNaO3 requires 390.2979).
tert-Butyl (2R,6R)-6-(4″-chlorobutyl)-2-methyl-4-oxopiperidine-
1-carboxylate (11g)
The reaction was carried out according to the above procedure
for the synthesis of tert-butyl (2R,6R)-2-methyl-4-oxo-6-propyl-
piperidine-1-carboxylate (11a) using (2R,5E)-2-(tert-butoxycar-
bonylamino)-10-chloro-4-oxodec-5-ene (10g) (0.0484 g,
0.0159 mmol). Purification by flash column chromatography
using silica gel, eluting with 20% diethyl ether in petroleum
ether (40–60) gave tert-butyl (2R,6R)-6-(4″-chlorobutyl)-2-
methyl-4-oxopiperidine-1-carboxylate (11g) (0.0269 g, 56%) as a
white solid. Mp 58–59 °C; νmax/cm
−1 (neat) 2975 (CH), 1725
(CvO), 1688 (CvO), 1390, 1366, 1174, 1097; [α]22D +120.1 (c 1.0,
CHCl3); δH (400 MHz, CDCl3) 1.25 (3H, d, J 6.6 Hz, 1′-H3),
1.30–1.47 (3H, m, 1-HH and 2″-H2), 1.49 (9H, s, 3 × CH3),
1.69–1.84 (3H, m, 3″-H2 and 1″-HH), 2.37 (1H, dd, J 17.8,
1.9 Hz, 3-HH), 2.52 (1H, dd, J 18.0, 2.0 Hz, 5-HH), 2.73 (1H,
ddd, J 18.0, 6.0, 0.8 Hz, 5-HH), 2.78 (1H, dd, J 17.8, 6.4 Hz,
3-HH), 3.51 (2H, t, J 6.5 Hz, 4″-H2), 4.09–4.24 (1H, m, 6-H),
4.26–4.43 (1H, m, 2-H); δC (101 MHz, CDCl3) 22.8 (CH3), 24.1
(CH2), 28.6 (3 × CH3), 32.3 (CH2), 36.5 (CH2), 41.5 (CH2), 44.7
(CH2), 44.8 (CH2), 46.7 (CH), 51.0 (CH), 80.2 (C), 154.7 (C),
207.9 (C); m/z (ESI) 326.1480 (MNa+. C15H26
35ClNNaO3 requires
326.1493).
tert-Butyl (2R,6R)-6-(2″-cyclohexylethyl)-2-methyl-4-
oxopiperidine-1-carboxylate (11h)
The reaction was carried out according to the above procedure
for the synthesis of tert-butyl (2R,6R)-2-methyl-4-oxo-6-propyl-
piperidine-1-carboxylate (11a) using (2R,5E)-2-(tert-butoxycar-
bonylamino)-8-cyclohexyl-4-oxodec-5-ene (10h) (0.0269 g,
0.0830 mmol). Purification by flash column chromatography
using silica gel, eluting with 20% diethyl ether in petroleum
ether (40–60) gave tert-butyl (2R,6R)-6-(2″-cyclohexylethyl)-2-
methyl-4-oxopiperidine-1-carboxylate (11h) (0.0149 g, 55%) as
a colourless oil. νmax/cm
−1 (neat) 2924 (CH), 1721 (CvO), 1690
(CvO), 1389, 1366, 1173, 1096; [α]25D +105.9 (c 0.4, CHCl3); δH
(400 MHz, CDCl3) 0.75–0.95 (2H, m, CH2), 1.05–1.38 (11H, m,
1′-H3, 1″-HH, 2″-H2, 3″-H, and 2 × CH2), 1.49 (9H, s, 3 × CH3),
1.60–1.84 (5H, m, 1″-HH and 2 × CH2), 2.36 (1H, dd, J 17.8,
1.9 Hz, 3-HH), 2.52 (1H, dd, J 17.9, 2.0 Hz, 5-HH), 2.71 (1H,
ddd, J 17.9, 6.2, 1.2 Hz, 5-HH), 2.80 (1H, dd, J 17.8, 6.4 Hz,
3-HH), 4.03–4.17 (1H, m, 6-H), 4.28–4.44 (1H, m, 2-H);
δC (101 MHz, CDCl3) 22.8 (CH3), 26.4 (2 × CH2), 26.7 (CH2),
28.7 (3 × CH3), 33.4 (CH2), 33.6 (CH2), 34.6 (CH2), 34.7 (CH2),
37.7 (CH), 41.4 (CH2), 44.7 (CH2), 46.6 (CH), 51.7 (CH), 80.0
(C), 154.7 (C), 208.3 (C); m/z (ESI) 346.2345 (MNa+.
C19H33NNaO3 requires 346.2353).
tert-Butyl (2R,6R)-2-methyl-4-oxo-6-(2″-phenylethyl)piperidine-
1-carboxylate (11i)
The reaction was carried out according to the above procedure
for the synthesis of tert-butyl (2R,6R)-2-methyl-4-oxo-6-propyl-
piperidine-1-carboxylate (11a) using (2R,5E)-2-(tert-butoxycar-
bonylamino)-4-oxo-8-phenyloct-5-ene (10i) (0.090 g, 0.284
mmol). Purification by flash column chromatography
using silica gel, eluting with 20% ethyl acetate in petroleum
ether (40–60) gave tert-butyl (2R,6R)-2-methyl-4-oxo-6-(2″-phe-
nylethyl)piperidine-1-carboxylate (11i) (0.045 g, 51%) as a
white solid. Mp 76–78 °C; νmax/cm
−1 (neat) 2973 (CH), 1724
(CvO), 1687 (CvO), 1389, 1366, 1173, 1096; [α]18D +97.7 (c 1.0,
CHCl3); δH (400 MHz, CDCl3) 1.27 (3H, d, J 6.7 Hz, 1′-H3), 1.49
(9H, s, 3 × CH3), 1.58–1.70 (1H, m, 1″-HH), 2.04–2.16 (1H, m,
1″-HH), 2.38 (1H, dd, J 17.8, 2.0 Hz, 3-HH), 2.54–2.69 (3H, m,
5-HH and 2″-H2), 2.77 (1H, dd, J 17.5, 5.6 Hz, 5-HH), 2.82
(1H, dd, J 17.8, 6.8 Hz, 3-HH), 4.20–4.30 (1H, m, 6-H),
4.31–4.43 (1H, m, 2-H), 7.12–7.32 (5H, m, Ph); δC (101 MHz,
CDCl3) 22.7 (CH3), 28.5 (3 × CH3), 33.2 (CH2), 39.0 (CH2),
41.4 (CH2), 44.6 (CH2), 46.6 (CH), 50.9 (CH), 80.1 (C), 126.1
(CH), 128.3 (2 × CH), 128.5 (2 × CH), 141.0 (C), 154.5 (C), 207.7
(C); m/z (ESI) 340.1875 (MNa+. C19H27NNaO3 requires
340.1883).
tert-Butyl (2R,6R)-2-methyl-6-(2″-methylpropyl)-4-
oxopiperidine-1-carboxylate (11j) and tert-butyl (2R,6S)-2-
methyl-6-(2″-methylpropyl)-4-oxopiperidine-1-carboxylate (12j)
The reaction was carried out according to the above procedure
for the synthesis of tert-butyl (2R,6R)-2-methyl-4-oxo-6-propyl-
piperidine-1-carboxylate (11a) using (2R,5E)-2-(tert-butoxycar-
bonylamino)-8-methyl-4-oxonon-5-ene (10j) (0.0804 g, 0.298
mmol). Purification by flash column chromatography using
silica gel, eluting with 20% diethyl ether in petroleum ether
(40–60) gave tert-butyl (2R,6R)-2-methyl-6-(2″-methylpropyl)-4-
oxopiperidine-1-carboxylate (11j) (0.032 g, 40%) and tert-butyl
(2R,6S)-2-methyl-6-(2″-methylpropyl)-4-oxopiperidine-1-carboxy-
late (12j) (0.032 g, 40%) as colourless oils. Data for tert-butyl
(2R,6R)-2-methyl-6-(2″-methylpropyl)-4-oxopiperidine-1-carbox-
ylate (11j): νmax/cm
−1 (neat) 2960 (CH), 1726 (CvO), 1688
(CvO), 1389, 1369, 1175; [α]28D +34.4 (c 0.2, CHCl3);
δH (500 MHz, CDCl3) 0.89 (3H, d, J 6.3 Hz, 3″-H3), 0.92 (3H, d,
J 6.3 Hz, 2″-CH3), 1.26 (3H, d, J 6.7 Hz, 1′-H3), 1.27–1.33 (1H,
m, 2″-H), 1.50 (9H, s, 3 × CH3), 1.52–1.58 (2H, m, 1″-H2), 2.36
(1H, dd, J 17.8, 2.0 Hz, 3-HH), 2.52 (1H, dd, J 17.9, 2.0 Hz,
5-HH), 2.72 (1H, ddd, J 17.9, 6.1, 1.0 Hz, 5-HH), 2.82 (1H, dd,
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J 17.8, 6.5 Hz, 3-HH), 4.22–4.30 (1H, m, 6-H), 4.31–4.39 (1H, m,
2-H); δC (126 MHz, CDCl3) 21.4 (CH3), 22.9 (CH), 23.9 (CH3),
25.5 (CH3), 28.7 (3 × CH3), 41.5 (CH2), 44.7 (CH2), 45.8 (CH2),
46.7 (CH), 49.4 (CH), 80.1 (C), 154.6 (C), 208.2 (C); m/z (ESI)
292.1877 (MNa+. C15H27NNaO3 requires 292.1883). Data for
tert-butyl (2R,6S)-2-methyl-6-(2″-methylpropyl)-4-oxopiperidine-
1-carboxylate (12j): νmax/cm
−1 (neat) 2961 (CH), 1721 (CvO),
1686 (CvO), 1352, 1171, 1125; [α]28D −4.0 (c 0.3, CHCl3);
δH (500 MHz, CDCl3) 0.91 (3H, d, J 6.5 Hz, 3″-H3), 0.94 (3H, d,
J 6.5 Hz, 2″-CH3), 1.26 (3H, d, J 7.0 Hz, 1′-H3), 1.33–1.44 (2H,
m, 1″-H2), 1.48 (9H, s, 3 × CH3), 1.51–1.59 (1H, m, 2″-H),
2.25–2.33 (2H, m, 3-HH and 5-HH), 2.59–2.73 (2H, m, 3-HH
and 5-HH), 4.58–4.82 (2H, m, 2-H and 6-H); δC (126 MHz,
CDCl3) 22.2 (CH3), 23.0 (CH), 23.2 (CH3), 25.4 (CH3), 28.6 (3 ×
CH3), 44.1 (CH2), 45.6 (CH2), 46.0 (CH2), 48.4 (CH), 50.8 (CH),
80.4 (C), 154.8 (C), 208.8 (C); m/z (ESI) 292.1877 (MNa+.
C15H27NNaO3 requires 292.1883).
tert-Butyl (2R,6R)-2-methyl-6-(1″-methylethyl)-4-oxopiperidine-
1-carboxylate (11k) and tert-butyl (2R,6S)-2-methyl-6-(1″-
methylethyl)-4-oxopiperidine-1-carboxylate (12k)
The reaction was carried out according to the above procedure
for the synthesis of tert-butyl (2R,6R)-2-methyl-4-oxo-6-propyl-
piperidine-1-carboxylate (11a) using (2R,5E)-2-(tert-butoxycar-
bonylamino)-7-methyl-4-oxooct-5-ene (10k) (0.103 g, 0.403
mmol). Purification by flash column chromatography using
silica gel, eluting with 20% diethyl ether in petroleum ether
(40–60) gave tert-butyl (2R,6R)-2-methyl-6-(1″-methylethyl)-4-
oxopiperidine-1-carboxylate (11k) (0.027 g, 27%) and tert-butyl
(2R,6S)-2-methyl-6-(1″-methylethyl)-4-oxopiperidine-1-carboxy-
late (12k) (0.027 g, 27%) as colourless oils. Data for tert-butyl
(2R,6R)-2-methyl-6-(1″-methylethyl)-4-oxopiperidine-1-carboxy-
late (11k): νmax/cm
−1 (neat) 2968 (CH), 1724 (CvO), 1688
(CvO), 1381, 1366, 1354, 1175; [α]27D +171.1 (c 0.2, CHCl3); δH
(500 MHz, CDCl3) 0.92 (3H, d, J 6.5 Hz, 2″-H3), 0.97 (3H, d,
J 6.5 Hz, 1″-CH3), 1.26 (3H, d, J 6.5 Hz, 1′-H3), 1.49 (9H, s, 3 ×
CH3), 1.60–1.72 (1H, m, 1″-H), 2.33 (2H, dd, J 17.5, 2.2 Hz,
3-HH), 2.59 (1H, dd, J 18.0, 2.6 Hz, 5-HH), 2.66 (1H, dd, J 18.0,
5.8 Hz, 5-HH), 2.79 (1H, dd, J 17.5, 6.5 Hz, 3-HH), 3.95–4.10
(1H, m, 6-H), 4.31 (1H, quin.d, J 6.5, 2.2 Hz, 2-H); δC
(126 MHz, CDCl3) 19.3 (CH3), 20.4 (CH3), 22.8 (CH3), 28.6 (3 ×
CH3), 35.1 (CH), 41.5 (CH2), 44.8 (CH2), 47.0 (CH), 56.3 (CH),
80.1 (C), 155.5 (C), 208.6 (C); m/z (ESI) 278.1722 (MNa+.
C14H25NNaO3 requires 278.1727). Data for tert-butyl (2R,6S)-2-
methyl-6-(1″-methylethyl)-4-oxopiperidine-1-carboxylate (12k):
νmax/cm
−1 (neat) 2972 (CH), 1718 (CvO), 1687 (CvO), 1365,
1172, 1120, 1066; [α]23D −47.6 (c 0.5, CHCl3); δH (500 MHz,
CDCl3) 0.93 (3H, d, J 6.5 Hz, 2″-H3), 0.97 (3H, d, J 6.5 Hz, 1″-
CH3), 1.30 (3H, d, J 6.8 Hz, 1′-H3), 1.48 (9H, s, 3 × CH3),
1.76–1.84 (1H, m, 1″-H), 2.29 (1H, ddd, J 15.5, 5.4, 0.9 Hz,
3-HH), 2.53–2.57 (2H, m, 5-H2), 2.67 (1H, dd, J 15.5, 7.7 Hz,
3-HH), 4.15–4.35 (1H, m, 6-H), 4.52–4.75 (1H, m, 2-H); δC
(126 MHz, CDCl3) 20.2 (CH3), 20.4 (CH3), 22.6 (CH3), 28.4 (3 ×
CH3), 33.0 (CH), 42.0 (CH2), 45.5 (CH2), 48.1 (CH), 58.5 (CH),
80.2 (C), 155.3 (C), 208.8 (C); m/z (ESI) 278.1720 (MNa+.
C14H25NNaO3 requires 278.1727).
(+)-Myrtine (1)10b
To a solution of tert-butyl (2R,6R)-6-(4″-chlorobutyl)-2-methyl-
4-oxopiperidine-1-carboxylate (11g) (0.049 g, 0.16 mmol) in
tetrahydrofuran (2 mL) was added aqueous 2 M hydrochloric
acid solution. The reaction mixture was stirred at room temp-
erature for 4 h. The reaction mixture was concentrated in vacuo
to aﬀord a yellow residue. This was dissolved in acetone (5 mL)
and saturated sodium hydrogen carbonate solution (3 mL) and
water (2 mL) were added. The reaction mixture was stirred at
room temperature for 48 h. The reaction mixture was poured
onto saturated sodium hydrogen carbonate solution (50 mL),
which was extracted with dichloromethane (3 × 50 mL). The
combined organic layers were washed with brine (50 mL),
dried (MgSO4) and concentrated in vacuo to give the crude
product as a yellow oil. Purification by flash column chromato-
graphy using silica gel, eluting with 4% methanol in dichloro-
methane gave (+)-myrtine (1) as a pale yellow oil (0.017 g,
62%). [α]24D +8.9 (c 0.3, CHCl3), lit.
10b [α]22D +10.5 (c 0.9, CHCl3);
δH (500 MHz, CDCl3) 0.95 (3H, d, J 6.8 Hz, 1′-H3), 1.15–1.35
(2H, m, 2″-HH and 3″-HH), 1.52–1.76 (4H, m, 1″-H2, 2″-HH and
3″-HH), 2.14–2.28 (3H, m, 3-HH and 4″-H2), 2.46 (1H, td,
J 11.6, 2.8 Hz, 5-HH), 2.60–2.69 (1H, m, 6-H), 2.74–2.80 (1H, m,
5-HH), 2.83 (1H, dd, J 13.4, 6.8 Hz, 3-HH), 3.37 (1H, quin.d,
J 6.8, 2.3 Hz, 2-H); δC (126 MHz, CDCl3) 11.2 (CH3), 23.5 (CH2),
26.0 (CH2), 34.4 (CH2), 48.2 (CH2), 48.8 (CH2), 51.5 (CH2), 53.6
(CH), 57.2 (CH), 209.7 (C); m/z (ESI) 168 (MH+, 100%).
(8R,10R)-8-Methyl-10-undecyl-1,5-dithia-9-azaspiro[5.5]
undecane (13)
A solution of tert-butyl (2R,6R)-2-methyl-4-oxo-6-undecylpiperi-
dine-1-carboxylate (11f ) (0.0570 g, 0.136 mmol) in anhydrous
dichloromethane (5 mL) was cooled to 0 °C and 1,3-propane-
dithiol (0.136 mL, 1.36 mmol) and boron trifluoride diethyl
etherate (0.042 mL, 0.340 mmol) was added dropwise. The
reaction was warmed to room temperature and stirred for 20 h.
The reaction mixture was then diluted with dichloromethane
(50 mL), washed with 1 M sodium hydroxide (50 mL) and
brine (50 mL). The organic layer was dried (MgSO4) and con-
centrated in vacuo to give the crude product as a yellow oil.
Purification by flash column chromatography using silica gel,
eluting with 5% methanol in dichloromethane gave (8R,10R)-8-
methyl-10-undecyl-1,5-dithia-9-azaspiro[5.5]undecane (13) as a
colourless oil (0.0500 g, 90%). νmax/cm
−1 (neat) 2922 (CH),
1465, 721; [α]24D +6.4 (c 1.0, CHCl3); δH (400 MHz, CDCl3) 0.88
(3H, t, J 6.9 Hz, 11″-H3), 1.16–1.41 (21H, m, 1′-H3, 2″-H2, 3″-H2,
4″-H2, 5″-H2, 6″-H2, 7″-H2, 8″-H2, 9″-H2 and 10″-H2), 1.58–1.76
(2H, m, 1″-H2), 1.86 (1H, dd, J 14.0, 7.4 Hz, 7-HH), 1.90–2.04
(3H, m, 3-H2 and 11-HH), 2.24 (1H, dd, J 14.2, 4.4 Hz, 11-HH),
2.29 (1H, dd, J 14.0, 3.9 Hz, 7-HH), 2.77–2.94 (4H, m, 2-H2 and
4-H2), 3.08–3.21 (1H, m, 10-H), 3.27–3.41 (1H, m, 8-H); δC
(101 MHz, CDCl3) 14.3 (CH3), 21.7 (CH3), 22.8 (CH2), 25.6
(CH2), 26.6 (2 × CH2), 26.8 (CH2), 29.7 (3 × CH2), 29.8 (2 ×
CH2), 32.1 (CH2), 35.1 (CH2), 41.3 (CH2), 44.0 (CH2), 45.0 (CH),
47.9 (CH2), 50.2 (CH); m/z (ESI) 358.2583 (MH
+. C20H40NS2
requires 358.2597).
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(−)-Solenopsin A (3)14b
To a solution of (8R,10R)-8-methyl-10-undecyl-1,5-dithia-9-azas-
piro[5.5]undecane (13) (0.0710 g, 0.155 mmol) in ethanol
(10 mL) was added a suspension of RANEY® nickel (1.58 g) in
ethanol (10 mL). The reaction mixture was heated under reflux
whilst purging with hydrogen for 0.5 h. The reaction was then
stirred under reflux, under an atmosphere of hydrogen for a
further 3 h. After cooling to room temperature, the reaction
mixture was filtered through a Celite pad and then concen-
trated in vacuo. The resulting residue was dissolved in di-
chloromethane (50 mL) and washed with 2 M sodium hydrox-
ide (50 mL) and brine (50 mL). The organic layer was dried
(MgSO4) and concentrated to give the crude product as a
yellow oil. Purification by flash column chromatography using
silica gel, eluting with 20% methanol in chloroform gave
(−)-solenopsin A (3) as a colourless oil (0.0301 g, 77%). [α]25D
−1.0 (c 0.5, MeOH), lit.14b [α]D −1.21 (c 0.94, MeOH); δH
(400 MHz, CDCl3) 0.88 (3H, t, J 6.9 Hz, 11″-H3), 1.07 (3H, d,
J 6.5 Hz, 1′-H3), 1.19–1.70 (26H, m, 3-H2, 4-H2, 5-H2, 1″-H2, 2″-
H2, 3″-H2, 4″-H2, 5″-H2, 6″-H2, 7″-H2, 8″-H2, 9″-H2 and 10″-H2),
2.87 (1H, qd, J 6.8, 4.4 Hz, 6-H), 3.06 (1H, quin.d, J 6.5, 3.6 Hz,
2-H); δC (101 MHz, CDCl3) 14.3 (CH3), 19.7 (CH2), 21.4 (CH3),
22.8 (CH2), 26.6 (CH2), 29.5 (CH2), 29.7 (3 × CH2), 29.8 (3 ×
CH2), 29.9 (CH2), 32.1 (CH2), 33.1 (CH2), 46.0 (CH), 51.0 (CH);
m/z (EI) 253 (M+, 11%), 238 (36), 210 (5), 126 (6), 111 (8), 98
(100).
Conﬂicts of interest
There are no conflicts to declare.
Acknowledgements
Financial support from EPSRC (studentships to J. D. B., EP/
N509176/1 and A. H. H., EP/K503058/1) and GlaxoSmithKline
is gratefully acknowledged.
Notes and references
1 (a) Alkaloids: Chemical and Biological Perspectives, ed.
S. W. Pelletier, Pergamon, Oxford, U.K., 1996, vol. 10;
(b) J. P. Michael, Nat. Prod. Rep., 2008, 25, 139.
2 (a) P. Slosse and C. Hootelé, Tetrahedron Lett., 1978, 19,
397; (b) P. Slosse and C. Hootelé, Tetrahedron, 1981, 37,
4287.
3 K. Fuji, T. Yamada, E. Fujita and H. Murata, Chem. Pharm.
Bull., 1978, 26, 2515.
4 (a) T. H. Jones, M. S. Blum and H. M. Fales, Tetrahedron,
1982, 38, 1949; (b) S. Leclercq, I. Thirionet, F. Broeders,
D. Daloze, R. Vander Meer and J. C. Braekman,
Tetrahedron, 1994, 50, 8465.
5 J. L. Arbiser, T. Kau, M. Konar, K. Narra, R. Ramchandran,
S. A. Summers, C. J. Vlahos, K. Ye, B. N. Perry, W. Matter,
A. Fischl, J. Cook, P. A. Silver, J. Bain, P. Cohen,
D. Whitmire, S. Furness, B. Govindarajan and J. P. Bowen,
Blood, 2007, 109, 560.
6 I. Karlsson, X. Zhou, R. Thomas, A. T. Smith, M. Y. Bonner,
P. Bakshi, A. K. Banga, J. P. Bowen, G. Qabaja, S. L. Ford,
M. D. Ballard, K. S. Peterson, X. G. Chen, B. Ogretmen,
J. Zhang, E. B. Watkins, R. S. Arnold and J. L. Arbiser, Vasc.
Cell, 2015, 7, DOI: 10.1186/s13221-015-0030-2.
7 (a) G. Ratle, X. Monseur, B. C. Das, J. Yassi, Q. Khuong-
Huu and R. Goutarel, Bull. Soc. Chim. Fr., 1966, 2945;
(b) Q. Khuong-Huu, G. Ratle, X. Monseur and R. Goutarel,
Bull. Soc. Chim. Belg., 1972, 81, 425.
8 P. Bourrinet and A. Quevauviller, Ann. Pharm. Fr., 1968, 26,
787.
9 For recent reviews, see: (a) N. Veerasamy and R. G. Carter,
Tetrahedron, 2016, 72, 4989; (b) N. Kandepedu,
I. Abrunhosa-Thomas and Y. Troin, Org. Chem. Front.,
2017, 4, 1655.
10 For selected recent examples, see: (a) C. Gnamm,
K. Brödner, C. M. Krauter and G. Helmchen, Chem. – Eur. J.,
2009, 15, 10514; (b) V. H. Vu, F. Louafi, N. Girard, R. Marion,
T. Roisnel, V. Dorcet and J.-P. Hurvois, J. Org. Chem., 2014,
79, 3358; (c) Y. Ying, H. Kim and J. Hong, Org. Lett., 2011,
13, 796; (d) H. Li and J. Wu, Org. Lett., 2015, 17, 5424;
(e) T. Hirama, T. Umemura, N. Kogure, M. Kitajima and
H. Takayama, Tetrahedron Lett., 2017, 58, 223; (f) W. Chen,
L. Ma, A. Paul and D. Seidel, Nat. Chem., 2018, 10, 165.
11 J. E. Baldwin, J. Chem. Soc., Chem. Commun., 1976, 734.
12 (a) M. G. Banwell, B. D. Bissett, C. T. Bui, H. T. T. Pham
and G. W. Simpson, Aust. J. Chem., 1998, 51, 9;
(b) E. L. Wynne, G. J. Clarkson and M. Shipman,
Tetrahedron Lett., 2008, 49, 250.
13 L. S. Fowler, L. H. Thomas, D. Ellis and A. Sutherland,
Chem. Commun., 2011, 47, 6569.
14 (a) I. Abrunhosa-Thomas, O. Roy, M. Barra, T. Besset,
P. Chalard and Y. Troin, Synlett, 2007, 1613;
(b) I. Abrunhosa-Thomas, A. Plas, A. Vogrig, N. Kandepedu,
P. Chalard and Y. Troin, J. Org. Chem., 2013, 78, 2511.
15 M. Daly, A. A. Cant, L. S. Fowler, G. L. Simpson, H. M. Senn
and A. Sutherland, J. Org. Chem., 2012, 77, 10001.
16 A. H. Harkiss and A. Sutherland, J. Org. Chem., 2018, 83, 535.
17 C. S. Dexter, R. F. W. Jackson and J. Elliott, J. Org. Chem.,
1999, 64, 7579.
18 T. Hjelmgaard and D. Tanner, Org. Biomol. Chem., 2006, 4,
1796.
19 The addition of Hünig’s base during the hydrodehalogena-
tion neutralises hydrogen iodide formed during this
process, thus preventing poisoning of the Pd/C catalyst.
See: (a) Y.-Y. Ku, Y.-M. Pu, T. Grieme, P. Sharma,
A. V. Bhatia and M. Cowart, Tetrahedron, 2006, 62, 4584;
(b) P. K. Mandal, J. S. Birtwistle and J. S. McMurray, J. Org.
Chem., 2014, 79, 8422.
20 L. S. Fowler, D. Ellis and A. Sutherland, Org. Biomol. Chem.,
2009, 7, 4309.
21 A similar cyclisation that initially produces the kinetic 2,6-
trans isomer and then the thermodynamic 2,6-cis product
Organic & Biomolecular Chemistry Paper
This journal is © The Royal Society of Chemistry 2018 Org. Biomol. Chem., 2018, 16, 6410–6422 | 6421
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 1
1 
Ju
ly
 2
01
8.
 D
ow
nl
oa
de
d 
on
 1
0/
23
/2
01
8 
11
:1
0:
54
 A
M
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
over an extended time period, via a retro-conjugate
addition process was also observed by Troin and co-
workers in their intramolecular Michael-type reaction
of carbamate-protected amine-substituted enones. See
ref. 14b.
22 It is well established that 2,6-cis-piperidines are the more
stable, thermodynamic isomer, while 2,6-trans-piperidines
are generated under kinetic conditions. See ref. 14b and:
(a) S. Ciblat, P. Calinaud, J.-L. Canet and Y. Troin, J. Chem.
Soc., Perkin Trans. 1, 2000, 353; (b) J. Quick, C. Mondello,
M. Humora and T. Brennan, J. Org. Chem., 1978, 43, 2705.
23 T. Markidis and G. Kokotos, J. Org. Chem., 2001, 66, 1919.
24 K. B. Hansen, T. Rosner, M. Kubryk, P. G. Dormer and
J. D. Armstrong, Org. Lett., 2005, 7, 4935.
Paper Organic & Biomolecular Chemistry
6422 | Org. Biomol. Chem., 2018, 16, 6410–6422 This journal is © The Royal Society of Chemistry 2018
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 1
1 
Ju
ly
 2
01
8.
 D
ow
nl
oa
de
d 
on
 1
0/
23
/2
01
8 
11
:1
0:
54
 A
M
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
